Pregnancy Related Clinical Trial
— ACDCOfficial title:
Alternating Cycle / Direct Confirmation Redox Project (AC/DC)
NCT number | NCT04157309 |
Other study ID # | HUM00171526 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | January 6, 2020 |
Est. completion date | January 4, 2021 |
Verified date | March 2021 |
Source | University of Michigan |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study will involve the collection and analysis of urine samples from non-pregnant women to determine the existence of alternating redox status between two consecutive menstrual cycles.
Status | Completed |
Enrollment | 45 |
Est. completion date | January 4, 2021 |
Est. primary completion date | January 4, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years to 30 Years |
Eligibility | Inclusion Criteria: 1. Female subject, between the years 18-30, at the time of consent. 2. Subject is willing to participate and is capable of giving informed consent. (Note: Consent must be obtained prior to any study-related procedures.) 3. Subject must be willing to comply with all study procedures and must be available to participate for the duration of the study. 4. Subject agrees to avoid alcohol, unapproved medications (prescription, OTC, or other), marijuana products, and illicit substances for 3 days prior to each urine collection. Exclusion Criteria: - 1. Subject is pregnant, or trying to or planning to become pregnant during the study. 2. Subject was pregnant within 1 year of beginning study, regardless of the outcome of pregnancy. 3. Subject who is breastfeeding. 4. Subject who is not menstruating for any reason or plans to undergo or change circumstances that might affect menstruation (e.g., certain athletic training regimens, significant dietary changes). 5. History of recent or current irregular menstrual cycles (as self-reported by the subject). 6. Subject reports she has been told by a medical professional that she is not ovulating (i.e., has anovulatory periods) at any time during the previous 12 months. 7. Subject is using or planning to use any method to regulate her periods. 8. Subject smokes (includes tobacco and marijuana) or vapes. 9. By history, subject has medical problems that might influence the results of the study, such as endocrinologic, renal, or hormonal problems. 10. Known polycystic ovarian syndrome (by history). 11. Subject is taking or planning to take hormones or hormone- enhancing/manipulating pharmaceuticals (including "morning after pill" [levonorgestrel], birth control pills, Clomid [clomiphene citrate], Femara [letrozole], Cialis [tadalafil]*, Viagra [sildenafil]* and similar medications) and/or agents to influence hormonal status such as herbal products or nutritional supplements. (*Not approved for use and should be avoided by women.) 12. Subject is using or planning to use hormonal contraceptives of any type, including oral contraceptives and intrauterine devices. 13. Subject is using or planning to use hormonal therapies for acne vulgaris or other conditions, including spironolactone, flutamide, metformin, or oral contraceptives used as acne therapies, including Ortho Tri-Cyclen (combination of norgestimate and ethinyl estradiol [EE]), Estrostep (combination of norethindrone acetate and EE), and Yaz/Yasmin (combination of drospirenone and EE). 14. Subject is using or planning to use estrogen products, including topicals/creams, for any purpose. 15. Subject is using or planning to use androgens or anabolic steroids (e.g., stanazolol/danazol) for any reason, including for training or athletic purposes.. 16. Subject has attempted or taken IVF or IUI treatment within the prior six months. 17. Subject has uncontrolled diabetes or other significant medical disorder that might, in the investigator's opinion, preclude completion of the study or suggest that an exclusion criterion will ensue. 18. Subject reports difficulty handling biologic fluids, specifically urine, or gives other reasons why she is hesitant to participate. |
Country | Name | City | State |
---|---|---|---|
United States | The University of Michigan | Ann Arbor | Michigan |
Lead Sponsor | Collaborator |
---|---|
University of Michigan | Urobiologics LLC |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Redox potential of urine | The redox potential will be measured over two consecutive cycles to determine the variability in the relative redox status in women's urine. | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05017974 -
Research on Improving Sleep During Pregnancy
|
N/A | |
Completed |
NCT03284515 -
Vaccination In Pregnancy Gene Signature: VIP Signature Study
|
||
Recruiting |
NCT05969795 -
Comparison of Live Birth Rate in Natural Cycle Single Euploid FET Versus Without Luteal Phase Support
|
Phase 1 | |
Recruiting |
NCT06051201 -
Innovation for Small-scale Experiments: ReceptIVFity Test
|
N/A | |
Recruiting |
NCT04828382 -
Prospective Study of Pregnancy in Women With Cystic Fibrosis
|
||
Enrolling by invitation |
NCT04527926 -
STEPuP: Prenatal Provider Education and Training to Improve Medication-assisted Treatment Use During Pregnancy
|
N/A | |
Recruiting |
NCT04278651 -
Early Antenatal Support for Iron Deficiency Anemia
|
Phase 4 | |
Recruiting |
NCT04405700 -
Measuring Adverse Pregnancy and Newborn Congenital Outcomes
|
||
Recruiting |
NCT06258902 -
Odevixibat Pregnancy and Lactation Surveillance Program: A Study to Evaluate the Safety of Odevixibat During Pregnancy and/or Lactation
|
||
Completed |
NCT05487196 -
Effectiveness of Clonidine, Dexmedetomidine, and Fentanyl Adjuncts for Labor Epidural Analgesia
|
Phase 2 | |
Completed |
NCT03750968 -
Lutein & Zeaxanthin in Pregnancy - Carotenoid Supplementation During Pregnancy: Ocular and Systemic Effects
|
Phase 2 | |
Enrolling by invitation |
NCT06127277 -
Next4You: A Fully Mobile Relationships Based Program for Youth in Foster Care
|
N/A | |
Completed |
NCT05897697 -
Assessing Women's Preferences for Postpartum Thromboprophylaxis: the Prefer-Postpartum Study
|
||
Recruiting |
NCT05899101 -
The Impact of Opioid and Cannabis Exposure on Fetal Growth
|
||
Completed |
NCT05502510 -
Assessing the Effectiveness and Efficacy of the MyHealthyPregnancy Application
|
||
Completed |
NCT04296396 -
Opioid Prescription After Cesarean Trial
|
Phase 3 | |
Not yet recruiting |
NCT06069869 -
Multiple Micronutrient Supplementation (MMS) Iron Dose Acceptability Crossover Trial
|
Phase 3 | |
Not yet recruiting |
NCT06069856 -
Multiple Micronutrient Supplementation (MMS) IFA- Iron Dose Acceptability Crossover Trial
|
Phase 3 | |
Not yet recruiting |
NCT06079918 -
Multiple Micronutrient Supplementation for Maternal Anemia Prevention in Tanzania
|
Phase 3 | |
Not yet recruiting |
NCT06163651 -
Evaluating a One-Year Version of the Parent-Child Assistance Program
|
N/A |